Randomised multicentre clinical trial to evaluate voriconazole pre-emptive genotyping strategy in patients with risk of aspergillosis: vorigenipharm study protocol

INTRODUCTION: Invasive aspergillosis is the most important cause of morbidity and mortality in patients with haematological diseases. At present, voriconazole is the first-line treatment for invasive fungal disease. The pharmacokinetic interindividual variability of voriconazole depends on genetic f...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:BMJ Open
Main Authors: Monserrat Villatoro, Jaime, García García, Irene, Bueno, David, de la Cámara, Rafael, Estébanez, Miriam, López de la Guía, Ana, Abad-Santos, Francisco, Antón, Cristina, Mejía, Gina, Otero, María José, Ramírez García, Elena, Frías Iniesta, Jesús, Carcas, Antonio, Borobia, Alberto M
Formato: Artigo
Idioma:Inglês
Publicado: BMJ Publishing Group 2020
Assuntos:
Genetics and Genomics
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7534724/
https://ncbi.nlm.nih.gov/pubmed/33004392
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmjopen-2020-037443
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares